Is Psychedelic Therapy Ready for FDA Approval?

Sam Harris speaks with Robin Carhart-Harris about psychedelic research and its therapeutic potential. They discuss the current state of the field, the FDA denial of MDMA-assisted therapy for PTSD, the critical role of set and setting, risks for vulnerable populations, the REBUS model of how psychedelics work on the brain, the default mode network and ego dissolution, microdosing, the neuroscience of consciousness, DMT entities, and other topics. Dr Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. He has designed human brain imaging studies with LSD, psilocybin, MDMA, and DMT, and several clinical trials of psilocybin therapy for severe mental illnesses, including 3 key trials in depression plus 2 further trials in anorexia and fibromyalgia syndrome. Dr Carhart-Harris founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world. In 2020, he was named among the top 31 medical scientists by The Times newspaper. Dr Carhart-Harris became the inaugural Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco in 2021, and in the same year, was listed in TIME magazine’s ‘100 Next’ - a list of emerging leaders from around the world who are shaping the future. Website: carhartharrislab.com SUBSCRIBE to gain access to all full-length episodes of the podcast at https://samharris.org/subscribe/ OR become a channel member to access episodes on YouTube. For those who can't afford the full subscription price, we offer partial scholarships https://www.samharris.org/subscribe/s... Stay updated on new episodes, essays, and events — subscribe to Sam Harris’s free newsletter: https://samharris.org/newsletter-signup/